Sulodexide

	WikiDoc Resources for Sulodexide
Articles
Most recent articles on Sulodexide Most cited articles on Sulodexide Review articles on Sulodexide Articles on Sulodexide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sulodexide Images of Sulodexide Photos of Sulodexide Podcasts & MP3s on Sulodexide Videos on Sulodexide
Evidence Based Medicine
Cochrane Collaboration on Sulodexide Bandolier on Sulodexide TRIP on Sulodexide
Clinical Trials
Ongoing Trials on Sulodexide at Clinical Trials.gov Trial results on Sulodexide Clinical Trials on Sulodexide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sulodexide NICE Guidance on Sulodexide NHS PRODIGY Guidance FDA on Sulodexide CDC on Sulodexide
Books
Books on Sulodexide
News
Sulodexide in the news Be alerted to news on Sulodexide News trends on Sulodexide
Commentary
Blogs on Sulodexide
Definitions
Definitions of Sulodexide
Patient Resources / Community
Patient resources on Sulodexide Discussion groups on Sulodexide Patient Handouts on Sulodexide Directions to Hospitals Treating Sulodexide Risk calculators and risk factors for Sulodexide
Healthcare Provider Resources
Symptoms of Sulodexide Causes & Risk Factors for Sulodexide Diagnostic studies for Sulodexide Treatment of Sulodexide
Continuing Medical Education (CME)
CME Programs on Sulodexide
International
Sulodexide en Espanol Sulodexide en Francais
Business
Sulodexide in the Marketplace Patents on Sulodexide
Experimental / Informatics
List of terms related to Sulodexide

Sulodexide
Clinical data
Routes of; administration	Oral, Subcutaneous, Intravenous
ATC code	B01AB11 (WHO) ;
Identifiers
CAS Number	57821-29-1;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%).

Pharmacology

The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.^[1] Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.^[2]

Uses

Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury^[3] and the treatment of diabetic nephropathy.^[4]^[5]^[6] In combination with Melatonin, Sulodexide have been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.^[7]^[8]

References

↑ Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev. 24 (3–4): 214–26. doi:10.1111/j.1527-3466.2006.00214.x. PMID 17214598.
↑ Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev. 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179.
↑ Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther. 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091.
↑ Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol. 18 (5): 568–574. PMID 16299683.
↑ Gambaro G, Venturini AP, Noonan DM; et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int. 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876.
↑ Škrhaa J, , J Perušičováb J; et al. (1997). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Diabetes Res Clin Practice. 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243.
↑ Neri G, Baffa C, De Stefano A; et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". J. Biol. Regul. Homeost. Agents. 23 (2): 103–10. PMID 19589291.
↑ Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.

[1] Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev. 24 (3–4): 214–26. doi:10.1111/j.1527-3466.2006.00214.x. PMID 17214598.

[2] Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev. 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179.

[3] Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther. 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091.

[4] Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol. 18 (5): 568–574. PMID 16299683.

[5] Gambaro G, Venturini AP, Noonan DM; et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int. 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876.

[6] Škrhaa J, , J Perušičováb J; et al. (1997). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Diabetes Res Clin Practice. 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243.

[7] Neri G, Baffa C, De Stefano A; et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". J. Biol. Regul. Homeost. Agents. 23 (2): 103–10. PMID 19589291.

[8] Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Clinical data
Routes of administration	Oral, Subcutaneous, Intravenous
ATC code	B01AB11 (WHO)
Identifiers
CAS Number	57821-29-1
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

Sulodexide

Overview

Pharmacology

Uses

References

Navigation menu